Skip to main content

Table 1 Dose escalation study design

From: A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

Dose Level Peginterferon alfa-2b Ipilimumab
−2 1 μg/kg/week 3 mg/kg
−1 2 μg/kg/week 3 mg/kg
1 3 μg/kg/week 3 mg/kg
2 3 μg/kg/week 10 mg/kg